MIAMI, Sept. 21, 2015—Global Stem Cells Group, in collaboration with medical software company Datamed SA Chile, has announced the plans to launch StemData, the first cloud-based electronic medical record system specifically designed for regenerative medicine practitioners.
The new StemData system will come programmed with the latest point of care regenerative medicine protocols and follow-up procedures to make it easy for stem cell practitioners to document patient progress and gather important data to establish the safety and efficacy of stem cell treatments in an doctor’s office environment. The system app will be marketed exclusively through Global Stem Cells Group and will be provided free of charge to affiliate physicians in the new Stem Cell Center network.
The cloud-based, server-less StemData solution will be accessible via web, iPad, iPhone, Google Glass and Apple Watch. Global Stem Cells Group and Datamed have utilized the development of the latest electronic medical record (EMR) systems to bring intelligent EMR technology to regenerative medicine specialists.
The StemData app will help regenerative medicine physicians increase efficiencies in their medical practices while improving both treatment and business outcomes. The app will intuitively adapt to each individual practitioner’s unique practice preferences.
To learn more, visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 
305-224-1858.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
